Athena Apfel

Athena Apfel

Auto-generated profile, based on publicly available information

Athena Apfel

Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
AMAki Morikawa
Aki Morikawa
JLJinju Li
Jinju Li
PUPeter Ulintz
Peter Ulintz
XCXu Cheng
Xu Cheng
AAAthena Apfel
Athena Apfel
NMNathan Merrill
Nathan Merrill
The development of novel therapies for brain metastases is an unmet need. Brain metastases may have unique molecular features that could be explored as therapeutic targets. A better understanding of the drug sensitivity of live cells coupled to molecular analyses will lead to a rational prioritization of therapeutic candidates. We evaluated the molecular profiles of 12 breast cancer brain metastases (BCBM) and matched primary breast tumors to identify potential therapeutic targets. We established six novel patient-derived xenograft (PDX) from BCBM from patients undergoing clinically indicated surgical resection of BCBM and used the PDXs as a drug screening platform to interrogate potential molecular targets. Many of the alterations were conserved in brain metastases compared with the matched primary. We observed differential expressions in the immune-related and metabolism pathways. The PDXs from BCBM captured the potentially targetable molecular alterations in the source brain metastases tumor. The alterations in the PI3K pathway were the most predictive for drug efficacy in the PDXs. The PDXs were also treated with a panel of over 350 drugs and demonstrated high sensitivity to histone deacetylase and proteasome inhibitors. Our study revealed significant differences between the paired BCBM and primary breast tumors with the pathways involved in metabolisms and immune functions. While molecular targeted drug therapy based on genomic profiling of tumors is currently evaluated in clinical trials for patients with brain metastases, a functional precision medicine strategy may complement such an approach by expanding potential therapeutic options, even for BCBM without known targetable molecular alterations. Significance: Examining genomic alterations and differentially expressed pathways in brain metastases may inform future therapeutic strategies. This study supports genomically-guided therapy for BCBM and further investigation into incorporating real-time functional evaluation will increase confidence in efficacy estimations during drug development and predictive biomarker assessment for BCBM.


9 June 2023
Verified
Other
Open access
PDF file
AMAki Morikawa
Aki Morikawa
JLJinju Li
Jinju Li
PUPeter Ulintz
Peter Ulintz
XCXu Cheng
Xu Cheng
AAAthena Apfel
Athena Apfel
NMNathan Merrill
Nathan Merrill
GSEA analysis using the oncogenic, KEGG, and GOBP gene sets.

21 June 2023
Verified
Other
Open access
AMAki Morikawa
Aki Morikawa
JLJinju Li
Jinju Li
PUPeter Ulintz
Peter Ulintz
XCXu Cheng
Xu Cheng
AAAthena Apfel
Athena Apfel
NMNathan Merrill
Nathan Merrill
The development of novel therapies for brain metastases is an unmet need. Brain metastases may have unique molecular features that could be explored as therapeutic targets. A better understanding of the drug sensitivity of live cells coupled to molecular analyses will lead to a rational prioritization of therapeutic candidates. We evaluated the molecular profiles of 12 breast cancer brain metastases (BCBM) and matched primary breast tumors to identify potential therapeutic targets. We established six novel patient-derived xenograft (PDX) from BCBM from patients undergoing clinically indicated surgical resection of BCBM and used the PDXs as a drug screening platform to interrogate potential molecular targets. Many of the alterations were conserved in brain metastases compared with the matched primary. We observed differential expressions in the immune-related and metabolism pathways. The PDXs from BCBM captured the potentially targetable molecular alterations in the source brain metastases tumor. The alterations in the PI3K pathway were the most predictive for drug efficacy in the PDXs. The PDXs were also treated with a panel of over 350 drugs and demonstrated high sensitivity to histone deacetylase and proteasome inhibitors. Our study revealed significant differences between the paired BCBM and primary breast tumors with the pathways involved in metabolisms and immune functions. While molecular targeted drug therapy based on genomic profiling of tumors is currently evaluated in clinical trials for patients with brain metastases, a functional precision medicine strategy may complement such an approach by expanding potential therapeutic options, even for BCBM without known targetable molecular alterations.Significance:Examining genomic alterations and differentially expressed pathways in brain metastases may inform future therapeutic strategies. This study supports genomically-guided therapy for BCBM and further investigation into incorporating real-time functional evaluation will increase confidence in efficacy estimations during drug development and predictive biomarker assessment for BCBM.

21 June 2023
Verified
Other
Open access
AMAki Morikawa
Aki Morikawa
JLJinju Li
Jinju Li
PUPeter Ulintz
Peter Ulintz
XCXu Cheng
Xu Cheng
AAAthena Apfel
Athena Apfel
NMNathan Merrill
Nathan Merrill
Drug responses (DSS3 values) matched to potentially actionable genomic alterations in BCBM PDX models

21 June 2023
Verified
Other
Open access
AMAki Morikawa
Aki Morikawa
JLJinju Li
Jinju Li
PUPeter Ulintz
Peter Ulintz
XCXu Cheng
Xu Cheng
AAAthena Apfel
Athena Apfel
NMNathan Merrill
Nathan Merrill
Drug responses (DSS3 values) matched to potentially actionable genomic alterations in BCBM PDX models